Ducentis BioTherapeutics
Witney
About Ducentis BioTherapeutics
Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Ducentis' target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the innate and adaptive arms of the immune system. Potential therapeutic targets include transplant rejection and autoimmune and inflammatory diseases affecting the lungs, liver, kidney, eye, bone, and cartilage.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.2M
- Funding stage: M&A
- Last round: Angel (Aug 2017)
- Website: ducentisbio.com
- Phone: +441993880504
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/ducentis-biotherapeutics-179765 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.